Results 231 to 240 of about 934,412 (371)

Gene Therapies in Atrial Fibrillation. [PDF]

J Cardiovasc Transl Res
O'Donnell C, Mikhailov A, Yoo S, Ghosh A, Arora R.   +4 more
europepmc   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference. [PDF]

Europace
Svennberg E, Merino JL, Andrade J, Anselmino M, Arbelo E, Boersma E, Boriani G, Breithardt G, Chung M, Chyou J, Cohen A, Nielsen JC, Dichtl W, Diederichsen SZ, Dobrev D, Doehner W, Dworatzek E, Fabritz L, Filgueiras-Rama D, Gimpelewicz C, Hack G, Hatem S, Healey J, Heidbuchel H, Hijazi Z, Holst AG, Hove-Madsen L, Jalife J, van Leerdam R, Linz D, Lip GYH, Lubitz S, de Melis M, Meyer R, Orczykowski M, Parwani AS, Porta-Sanchez A, de Potter T, Ravens U, Rienstra M, Rillig A, Rivard L, Scherr D, Schnabel RB, Schotten U, Simovic S, Sinner M, Sohns C, Sommer P, Steinbeck G, Steven D, Sultan A, Thomalla G, Toennis T, Tzeis S, Voigt N, Wadhwa M, Wakili R, Witt H, Goette A, Kirchhof P.   +60 more
europepmc   +1 more source

Matrix metalloproteinase‐9 gene polymorphisms are associated with ischemic stroke severity and early neurologic deterioration in patients with atrial fibrillation [PDF]

, 2019
Xingyang Yi, Qiang Zhou, Guo Sui, Daofeng Fan, Yongyin Zhang, Minjie Shao, Zhao Han, Hua Luo, Jing Lin, Ju Zhou   +9 more
openalex   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Cardiac Resynchronization in Patients with Atrial Fibrillation.

, 2015
S. Serge Barold, Bengt Herweg
openalex   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

The Global Impact of Atrial Fibrillation. [PDF]

Arrhythm Electrophysiol Rev
Karatela MF, Calkins H.
europepmc   +1 more source

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

European Heart Journal, 2018
J. Steffel, P. Verhamme, T. Potpara, P. Albaladéjo, M. Antz, L. Desteghe, K. Haeusler, J. Oldgren, H. Reinecke, V. Roldán-Schilling, N. Rowell, P. Sinnaeve, R. Collins, A. Camm, H. Heidbüchel, G. Lip, J. Weitz, L. Fauchier, D. Lane, G. Boriani, A. Goette, R. Keegan, R. Macfadyen, C. Chiang, B. Joung, W. Shimizu   +25 more
semanticscholar   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source